Home LiteratureArticle Details
PMID: 19099489 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine.

The Journal of infectious diseases ·Vol. 199 ·No. 3 ·2009-02-01 ·Pages 320-5

Nahm MH, Lin J, Finkelstein JA, Pelton SI

Abstract

Because pneumococcal serotype 6C was previously not distinguished from serotype 6A, the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on the carriage of serotype 6C is unknown. The nasopharyngeal (NP) prevalence of the 6C serotype was determined using 1326 pneumococcal isolates collected from 7 cohorts of Massachusetts children between 1994 and 2007. Initially, the isolates were serotyped using the quellung reaction; subsequently, stored specimens of all putative 6A isolates were tested for 6C using monoclonal antibodies. The opsonophagocytic and antibiotic susceptibilities of the isolates were determined. The prevalence of 6A was 9.6% (33/343) before 2001, 8.0% (18/226) in 2004, and 2.9% (12/416) in 2007. In contrast, the prevalence of 6C was 0.6% (2/343) before 2001, 2.2% (5/226) in 2004, and 8.7% (36/416) in 2007 (P<.001 for 2/343 vs. 36/416). 6C isolates from 2007 were more susceptible to antibiotics than were 6A isolates. PCV7 induced a low ability to opsonize different isolates of 6C. Among NP isolates, the prevalence of 6C isolates has increased and the prevalence of 6A isolates has decreased since the introduction of PCV7 in Massachusetts in 2000. The observed increase in serotype 6C prevalence may be explained by the induction by PCV7 of low amounts of functional anti-6C antibody, compared with anti-6A and anti-6B antibodies.

MeSH Terms
Anti-Bacterial Agents/pharmacology Carrier State/epidemiology,microbiology Child Child, Preschool Drug Resistance, Multiple, Bacterial Heptavalent Pneumococcal Conjugate Vaccine Humans Infant Massachusetts/epidemiology Nasopharynx/microbiology Pneumococcal Infections/epidemiology,microbiology Pneumococcal Vaccines/administration & dosage,adverse effects Prevalence Serotyping Streptococcus pneumoniae/classification,immunology,isolation & purification Time Factors Vaccines, Conjugate/administration & dosage,adverse effects
Chemicals
Anti-Bacterial Agents Heptavalent Pneumococcal Conjugate Vaccine Pneumococcal Vaccines Vaccines, Conjugate
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Nahm Moon H
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. [email protected]
Lin Jisheng
Finkelstein Jonathan A
Pelton Stephen I
References (28)
28 references, click to expand
  1. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study.
    Clin Infect Dis. 2008 Mar 15;46(6):807-14 PMID: 18279039
  2. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.
    J Infect Dis. 1999 Oct;180(4):1171-6 PMID: 10479145
  3. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children.
    Pediatr Infect Dis J. 2008 Apr;27(4):335-40 PMID: 18316986
  4. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.
    Pediatr Infect Dis J. 2000 Mar;19(3):187-95 PMID: 10749457
  5. Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae.
    Pediatr Infect Dis J. 2003 Feb;22(2):e1-11 PMID: 12586987
  6. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Vaccine. 2007 Jul 20;25(29):5390-8 PMID: 17583392
  7. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.
    J Infect Dis. 2002 Apr 1;185(7):927-36 PMID: 11920317
  8. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005.
    J Infect Dis. 2008 Apr 1;197(7):1016-27 PMID: 18419539
  9. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.
    Pediatr Infect Dis J. 2007 Jun;26(6):468-72 PMID: 17529860
  10. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine.
    J Infect Dis. 1996 Dec;174(6):1271-8 PMID: 8940218
  11. Validation of a multiplex pneumococcal serotyping assay with clinical samples.
    J Clin Microbiol. 2006 Feb;44(2):383-8 PMID: 16455888
  12. Genetic basis for the new pneumococcal serotype, 6C.
    Infect Immun. 2007 Sep;75(9):4482-9 PMID: 17576753
  13. Differential effects of pneumococcal vaccines against serotypes 6A and 6C.
    J Infect Dis. 2008 Dec 15;198(12):1818-22 PMID: 18983249
  14. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.
    Pediatrics. 2005 Sep;116(3):e408-13 PMID: 16140686
  15. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates.
    Pediatr Infect Dis J. 2004 Nov;23(11):1015-22 PMID: 15545856
  16. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8 PMID: 18272956
  17. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.
    Pediatrics. 2000 Aug;106(2 Pt 1):362-6 PMID: 10920169
  18. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies.
    Clin Vaccine Immunol. 2006 Sep;13(9):1004-9 PMID: 16960111
  19. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae.
    J Clin Microbiol. 2007 Apr;45(4):1225-33 PMID: 17267625
  20. A rapid pneumococcal serotyping system based on monoclonal antibodies and PCR.
    J Med Microbiol. 2008 Feb;57(Pt 2):171-178 PMID: 18201982
  21. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.
    J Infect Dis. 2007 Nov 1;196(9):1346-54 PMID: 17922399
  22. Low prevalence of recently discovered pneumococcal serotype 6C isolates among healthy Dutch children in the pre-vaccination era.
    Vaccine. 2008 Jan 24;26(4):449-50 PMID: 18093702
  23. Molecular characterization of equine isolates of Streptococcus pneumoniae: natural disruption of genes encoding the virulence factors pneumolysin and autolysin.
    Infect Immun. 1999 Jun;67(6):2776-82 PMID: 10338480
  24. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.
    JAMA. 2007 Apr 25;297(16):1784-92 PMID: 17456820
  25. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.
    Clin Vaccine Immunol. 2006 Feb;13(2):165-9 PMID: 16467321
  26. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.
    N Engl J Med. 2006 Apr 6;354(14):1455-63 PMID: 16598044
  27. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.
    J Infect Dis. 1999 Nov;180(5):1569-76 PMID: 10515817
  28. Streptococcus pneumoniae serotype 19A in children, South Korea.
    Emerg Infect Dis. 2008 Feb;14(2):275-81 PMID: 18258121
Article Info
Journal
The Journal of infectious diseases
Abbr.
J Infect Dis
ISSN
0022-1899
DOI
10.1086/596064
Email
[email protected]
Published
2009-02-01
Pages
320-5
Language
English
Region
United States
NLM ID
0413675
PMCID
PMC2743180
Subset
IM
Grants
NIAID NIH HHS · R01 AI066304-03 · United States
NIAID NIH HHS · R01 AI-66304-01A1 · United States
NIAID NIH HHS · R01 AI031473 · United States
NIAID NIH HHS · R01 AI066304 · United States
NIAID NIH HHS · R01 AI-31473 · United States
External Links
PubMed source DOI: 10.1086/596064 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2